Answers are grounded in this paper and cite their sources.
The overall survival for patients with relapsed metastatic osteosarcoma (OS) remains stagnant at <25%. Dendritic cell vaccines (DCVs) induce antigen-specific anti-tumor immunity. We previously demonstrated that an ex vivo-generated DCV using CD103+ DCs (cDCs) and K7M3 OS lysates (K7M3 lysate-cDCV) induced systemic anti-tumor immunity. Targeting tumor-associated antigens (TAAs) using recombinant proteins offers a more efficient, tumor-independent alternative to using tumor lysates. CD70, a TAA, is overexpressed on multiple solid tumors including OS but not normal tissue. Incubation of cDCs with K7M3 lysates or recombinant CD70 in presence of poly I:C upregulated the expression of antigen-presenting and co-stimulatory molecules necessary for antigen presentation to T cells. The CD70-primed cDCs demonstrated comparable activity to K7M3 lysate-primed cDCs in inducing T-cell proliferation and IFNγ expression, and activating T-cell mediated tumor cell cytotoxicity. Using a bilateral subcutaneous tumor model, we showed that CD70-cDCV induced localized and systemic anti-tumor immune responses, inhibiting the growth of both the treated and untreated tumors. Pre-treatment with CD70-cDCV prevented the development of OS lung metastases and prolonged overall survival. Finally, intravenous administration of CD70-cDCV into mice with established OS lung metastases resulted in fewer and smaller lung tumors and improved survival. The CD70-cDCV demonstrated comparable anti-tumor activity to K7M3 lysate-cDCV. By contrast, no therapeutic activity was seen using lysates from CD70-knocked down K7M3 cells (CD70KD-cDCV), suggesting a critical role for CD70. Immunofluorescence staining of tumor-bearing lungs revealed increased infiltration of CD4 and CD8 T cells in mice treated with K7M3 lysate-cDCV or CD70-cDCV but not CD70KD-cDCV. Collectively, these findings indicate that targeting CD70 using a CD70-cDCV generates an effective anti-tumor response against OS and therefore serves as an alternative approach to using tumor lysates. CD70-cDCV may provide a new immunotherapeutic strategy against metastatic OS.
No takes yet. Share an insight, caveat, or question.
Shrestha et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: